Aimei Health II SPAC Eyes $60M IPO, China Ties Raise Red Flags

TL;DR

**Avoid Aimei Health Technology II; its deep China ties and inherent SPAC conflicts of interest make it a high-risk gamble for public shareholders.**

AI Summary

Aimei Health Technology II Co., Ltd, a Cayman Islands-incorporated blank check company, filed an S-1/A to offer 6,000,000 units at $10.00 each, aiming to raise $60,000,000 for a business combination within 12 months. Each unit comprises one Class A ordinary share and one right to receive one-seventh of a Class A ordinary share. The company's sponsor, Aimei Investment II Ltd, and several officers and directors, including Ms. Han Huang (sole beneficial owner of the sponsor and a PRC citizen) and Mr. Heung Ming Wong (CEO, CFO, Director, and Hong Kong resident), have significant ties to China. These ties may steer the company towards a PRC target, introducing additional risks and potential delays. The sponsor purchased 1,725,000 Class B ordinary shares for $25,000 and committed to buying 285,234 private units for $2,852,340. Public shareholders face immediate and substantial dilution, with pro forma net tangible book value per share ranging from $6.14 (25% redemptions) to $1.45 (maximum redemptions) compared to the $8.75 offering price (adjusted for rights value). The filing highlights significant conflicts of interest due to the financial incentives of the sponsor, officers, and directors, who may prioritize a quicker, less optimal business combination to meet the 12-month deadline.

Why It Matters

This S-1/A filing reveals Aimei Health Technology II's intent to raise $60 million, but its significant ties to China, through its sponsor and key executives, introduce substantial geopolitical and regulatory risks for investors. The potential for a PRC target company could expose the combined entity to increased scrutiny and operational complexities, impacting its competitive standing against SPACs with broader geographic mandates. For employees and customers of a potential target, the SPAC's 12-month deadline and potential conflicts of interest among its leadership could lead to a rushed or suboptimal merger, affecting long-term stability and value creation. The substantial dilution for public shareholders, ranging from $2.61 to $7.30 per share, underscores the immediate financial risk, making it crucial for investors to weigh the potential rewards against these inherent structural and operational challenges.

Risk Assessment

Risk Level: high — The risk level is high due to significant conflicts of interest and potential for substantial dilution. The sponsor and officers have strong ties to China, increasing the likelihood of pursuing a PRC target, which carries 'additional costs, delays, uncertainties, and liabilities' as stated on page 42. Public shareholders face immediate dilution, with pro forma net tangible book value per share as low as $1.45 in a maximum redemption scenario, compared to the $8.75 offering price (adjusted for rights value), representing a $7.30 dilution. Furthermore, the sponsor's insider shares were purchased at a nominal $0.014 per share, creating a strong incentive for them to complete any deal, even if it's not optimal for public shareholders.

Analyst Insight

Investors should exercise extreme caution and thoroughly scrutinize any potential business combination target, especially given the stated conflicts of interest and the significant dilution risk. Consider the 12-month deadline as a potential driver for a rushed deal. Given the high risk and potential for value destruction for public shareholders, a 'wait and see' approach or outright avoidance may be prudent until a definitive, well-vetted target is identified.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $60,000,000 — Total offering amount (Proceeds from 6,000,000 units at $10.00 each)
• 6,000,000 — Number of units offered (Each unit priced at $10.00)
• 12 months — Deadline for business combination (Period from closing of offering to consummate initial business combination)
• $10.00 — Price per unit (Offering price for each public unit)
• 1,725,000 — Class B ordinary shares purchased by sponsor (Purchased for an aggregate of $25,000)
• $0.014 — Purchase price per insider share (Nominal price paid by sponsor for Class B ordinary shares)
• $2,852,340 — Private units purchase commitment (Sponsor's commitment to purchase 285,234 private units at $10.00 each)
• $1.45 — Pro forma net tangible book value per share (maximum redemptions) (Represents significant dilution from the $8.75 adjusted offering price)
• $7.30 — Dilution to public shareholders (maximum redemptions) (Difference between adjusted offering price and pro forma net tangible book value per share)
• $5,000,001 — Minimum net tangible assets (Threshold below which the company will not redeem public shares)

Key Players & Entities

• Aimei Health Technology II Co., Ltd (company) — Registrant and blank check company
• Aimei Investment II Ltd (company) — Sponsor of the SPAC
• Han Huang (person) — Sole beneficial owner of the sponsor, citizen and resident of PRC
• Heung Ming Wong (person) — Chief Executive Officer, Chief Financial Officer, and Director, citizen and resident of Hong Kong
• David Zhang (person) — Independent director appointee, citizen of PRC and permanent resident of the United States
• A.G.P./Alliance Global Partners (company) — Representative of the underwriters
• Rimon, P.C. (company) — Legal counsel
• Thompson Hine LLP (company) — Legal counsel
• SEC (regulator) — U.S. Securities and Exchange Commission
• Cayman Islands (regulator) — Jurisdiction of incorporation

FAQ

Risk Factors

• Significant dilution for public shareholders [high — financial]: Public shareholders face immediate and substantial dilution. Pro forma net tangible book value per share is estimated to be as low as $1.45 at maximum redemptions, compared to the adjusted offering price of $8.75 (considering the unit price of $10.00 and the value of the rights). This represents a potential dilution of $7.30 per share.
• Potential PRC target risks [high — regulatory]: The sponsor and key officers/directors have significant ties to China, increasing the likelihood of pursuing a PRC target. This could lead to additional costs, delays, uncertainties, and liabilities, making it harder to complete a business combination within the 12-month deadline and potentially hindering shareholder rights.
• Sponsor's financial incentives and conflicts of interest [high — financial]: The sponsor purchased Class B shares for a nominal $0.014 per share and committed to private unit purchases. This financial incentive structure, coupled with the 12-month deadline, may lead the sponsor and management to prioritize a quicker, potentially less optimal, business combination to ensure their investment is realized.
• Limited time to complete business combination [high — operational]: The company has only 12 months from the closing of the offering to identify and complete an initial business combination. Failure to do so will result in the company liquidating and returning funds to shareholders, which could be insufficient to cover all expenses.
• Minimum net tangible asset requirement [medium — financial]: The company's charter prohibits redemptions that would cause its net tangible assets to fall below $5,000,001. This threshold could limit redemption rights for public shareholders in certain scenarios.
• Limitations on redemption rights [medium — legal]: Shareholders holding 15% or more of the shares sold in the offering may be restricted from seeking redemption rights without prior consent, potentially limiting their ability to exit their investment if they disagree with a proposed business combination.

Industry Context

The blank check company landscape, particularly SPACs focused on health technology, is highly competitive. Companies in this sector often seek to leverage technology to improve healthcare delivery, diagnostics, or patient outcomes. Trends include the increasing adoption of digital health solutions, AI in medical research, and personalized medicine. However, the regulatory environment for health technology is complex and evolving, requiring significant compliance efforts.

Regulatory Implications

As a Cayman Islands-incorporated entity with potential ties to PRC targets, Aimei Health Technology II faces scrutiny regarding cross-border transactions and compliance with both U.S. securities laws and potentially Chinese regulations. The significant influence of PRC-connected individuals may trigger heightened review by regulatory bodies concerning national security or data privacy, potentially leading to delays or increased compliance burdens.

What Investors Should Do

1. Scrutinize the target business combination carefully.
2. Assess the impact of potential redemptions on deal viability.
3. Understand the dilution from sponsor shares and rights.
4. Evaluate the risks associated with a potential PRC target.

Glossary

Blank Check Company

A shell company that is set up to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. Also known as a Special Purpose Acquisition Company (SPAC). (Aimei Health Technology II Co., Ltd. is structured as a blank check company, indicating its primary purpose is to find and merge with an operating business.)

Unit

A security that combines two or more different types of securities, typically a share and a warrant or right, offered together as a single package. (The offering consists of units, each containing one Class A ordinary share and one right to receive 1/7th of a Class A ordinary share, impacting the overall structure and potential dilution.)

Right

A security that gives the holder the option to purchase additional securities, often at a specified price, or in this case, to receive a fraction of a share upon a business combination. (The rights included in the units represent potential future dilution and are a component of the unit's overall value and the calculation of net tangible book value.)

Class B Ordinary Shares

Shares typically held by the sponsor of a SPAC, often with different voting rights or conversion features compared to Class A shares, and usually purchased at a nominal price. (The sponsor's purchase of 1,725,000 Class B shares for $25,000 highlights their significant stake and potential for control or influence.)

Sponsor

The entity or individuals who organize and fund a SPAC, typically receiving founder shares (Class B) and private placement warrants or units in exchange for their initial capital and expertise. (Aimei Investment II Ltd. is the sponsor, and its ownership and financial commitments are critical to the SPAC's structure and potential conflicts of interest.)

Redemption Rights

The right of public shareholders to demand that the SPAC repurchase their shares for cash, typically at the per-share price held in trust, if a business combination is not completed or if they vote against a proposed combination. (These rights are a key feature for public investors, offering an exit strategy but also impacting the amount of cash available for a business combination and potentially leading to dilution if many shareholders redeem.)

Net Tangible Book Value Per Share

A measure of a company's book value that excludes intangible assets like goodwill and patents, divided by the number of outstanding shares. It indicates the liquidation value per share. (The low pro forma net tangible book value per share ($1.45 at maximum redemptions) clearly illustrates the significant dilution experienced by public shareholders.)

Business Combination

The merger, acquisition, or other transaction through which a SPAC combines with an operating company. (The primary objective of Aimei Health Technology II Co., Ltd. is to identify and complete a business combination within a specified timeframe.)

Year-Over-Year Comparison

This is an S-1/A filing, representing an amendment to the initial S-1 registration statement. As such, it is an early-stage filing for a blank check company with no historical operating revenue or financial performance to compare against a prior year. The primary changes and focus are on detailing the offering structure, risks, and the company's proposed path to a business combination, rather than comparing operational metrics.

Key Financial Figures

• $60,000,000 — SUBJECT TO COMPLETION, DATED , 2025 $60,000,000 Aimei Health Technology II Co., Ltd
• $10.00 — nit that we are offering has a price of $10.00 and consists of one Class A ordinary sh
• $0.0001 — f one Class A ordinary share, par value $0.0001 per share, which we refer to as our "pu
• $100,000 — able and, subject to an annual limit of $100,000, amounts released to us to fund our wor
• $5,000,001 — our net tangible assets to be less than $5,000,001. If we anticipate that we may not be a
• $25,000 — e "insider shares") for an aggregate of $25,000 (or approximately $0.014 per share) on
• $0.014 — aggregate of $25,000 (or approximately $0.014 per share) on November 29, 2024, up to
• $2,852,340 — vate unit for a total purchase price of $2,852,340 (or up to $2,987,340 if the underwriter
• $2,987,340 — purchase price of $2,852,340 (or up to $2,987,340 if the underwriters' over-allotment opt
• $400,000 — (i) repayment of an aggregate of up to $400,000 in loans made to us by our sponsor unde
• $10,000 — ffering; (ii) payment to our sponsor of $10,000 per month from the closing of this offe
• $1,500,000 — vate units upon the conversion of up to $1,500,000 of such loans at a price of $10.00 per
• $8.75 — m redemptions (4) Offering price of $8.75 included in the units (adjusted to incl
• $5,000,0001 — t us to maintain net tangible assets of $5,000,0001) are redeemed. With Over-Allotment Opt
• $69,000,000 — e of the private units, $60,000,000, or $69,000,000 if the underwriters' over-allotment opt

Filing Documents

• afjku_s1a.htm (S-1/A) — 2347KB
• afjku_ex32.htm (EX-3.2) — 374KB
• afjku_ex101.htm (EX-10.1) — 52KB
• afjku_ex231.htm (EX-23.1) — 2KB
• afjku_ex231img1.jpg (GRAPHIC) — 2KB
• afjku_ex231img2.jpg (GRAPHIC) — 4KB
• 0001929980-25-000700.txt ( ) — 2785KB

From the Filing

afjku_s1a.htm As filed with the U.S. Securities and Exchange Commission on November 6, 2025. Registration No. 333-284015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________________ AIMEI HEALTH TECHNOLOGY II CO., LTD (Exact name of registrant as specified in its charter) __________________________________________ Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 10 East 53rd Street, Suite 3001 New York, NY 10022 +34 678 035200 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) __________________________________________ [ ] (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Olivia Y. Wang, Esq. Rimon, P.C. 400 Madison Ave, Suite 11D New York, NY 10017 (718) 504-9773 Faith Charles, Esq. Thompson Hine LLP 300 Madison Ave, 27th Floor New York, NY 10017 (212) 344-5680 __________________________________________ Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. The information in this preliminary prospectus is not complete and may be changed. We may not sell the securities being offered until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. PRELIMINARY PROSPECTUS $60,000,000 Aimei Health Technology II Co., Ltd 6,000,000 Units Aimei Health Technology II Co., Ltd is a blank check company incorporated under the laws of the Cayman Islands as an exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. We have 12 months from the closing of this offering to consummate our initial business combination. We have not selected any business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, including any company based in or having the majority of its operations in

View Full Filing

View this S-1/A filing on SEC EDGAR